Ensemble Therapeutics Corporation is a privately held pharmaceutical and biotechnology company in Cambridge, Massachusetts. Founded in 2004 by Harvard chemist David R. Liu, the company develops and is attempting to bring to market synthetic macrocycle drugs, that is, compounds with a characteristic macrocyclic ring structure, under the trademark Ensemblins. If successful, Ensemblins would be a new class of drugs between small molecules and biologics.

Property Value
dbo:abstract
  • Ensemble Therapeutics Corporation is a privately held pharmaceutical and biotechnology company in Cambridge, Massachusetts. Founded in 2004 by Harvard chemist David R. Liu, the company develops and is attempting to bring to market synthetic macrocycle drugs, that is, compounds with a characteristic macrocyclic ring structure, under the trademark Ensemblins. If successful, Ensemblins would be a new class of drugs between small molecules and biologics. An orally active antagonist to Interleukin 17 has been demonstrated in animal models. (en)
dbo:foundedBy
dbo:industry
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2017-09-29 15:44:10Z (xsd:date)
  • 2017-11-26 11:53:40Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 39262173 (xsd:integer)
dbo:wikiPageLength
  • 3924 (xsd:integer)
dbo:wikiPageModified
  • 2017-10-31 01:02:40Z (xsd:date)
dbo:wikiPageOutDegree
  • 25 (xsd:integer)
dbo:wikiPageRevisionID
  • 807954120 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:founder
  • David R. Liu (en)
dbp:homepage
dbp:industry
dbp:keyPeople
  • Michael D. Taylor (en)
  • Nick K. Terrett (en)
dbp:locationCity
dbp:locationCountry
  • United States (en)
dbp:logo
dbp:name
  • Ensemble Therapeutics Corp. (en)
dbp:products
  • Ensemblins™ (en)
dbp:type
  • private (en)
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Ensemble Therapeutics Corporation is a privately held pharmaceutical and biotechnology company in Cambridge, Massachusetts. Founded in 2004 by Harvard chemist David R. Liu, the company develops and is attempting to bring to market synthetic macrocycle drugs, that is, compounds with a characteristic macrocyclic ring structure, under the trademark Ensemblins. If successful, Ensemblins would be a new class of drugs between small molecules and biologics. (en)
rdfs:label
  • Ensemble Therapeutics (en)
owl:sameAs
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Ensemble Therapeutics Corp. (en)
is foaf:primaryTopic of